Vancouver, British Columbia–(Newsfile Corp. – January 19, 2024) – Defense Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“defense” or “company”), one of Canada's leading biotechnology companies working in the field of immuno-oncology, announced a funding amendment in addition to a news release on January 12, 2024.
The Company plans to conduct a non-brokered private placement of up to $2.25 million consisting of 1.5 million units of the Company. Each unit consists of one common share of the Company's capital stock and one stock purchase right. Each warrant entitles the holder to acquire one additional share at a price of $2.00 per share for a period of 24 months from the closing date.
The Company intends to use the net proceeds to advance its preclinical and clinical programs, including the previously announced Phase I clinical trial of Defense's AccuTOX.® It is administered intratumorally to patients with stage IIIB to IV melanoma and is given as general working capital. We may pay finder fees in connection with the Offering in accordance with CSE's policies. The securities issued in connection with the Offering are subject to a statutory storage period of four months and one day from the date of closing in accordance with the CSE.
Regarding defense:
Defense Therapeutics is a publicly traded biotechnology company working to develop next-generation vaccines and ADC products using a proprietary platform. At the core of the Defense Therapeutics platform is ACCUM® This technology allows for precise delivery of intact vaccine antigens or ADCs to target cells. The result is increased effectiveness and potency against devastating diseases such as cancer and infectious diseases.
For more information:
Sebastian Plouffe, President, CEO, Director
Phone: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Notes regarding “forward-looking” information
This release contains certain statements that may be considered “forward-looking statements.” All statements, other than statements of historical fact, in this release about events or developments that the Company expects to occur are forward-looking statements. Forward-looking statements are statements that are not historical facts and generally include, but are not limited to, “expect,” “plan,” “anticipate,” “believe,” “intend,” or “estimate.” , identified by the word “to plan.” , “potential” and similar expressions, or when an event or condition “will”, “will”, “could”, “could”, or “should” occur. “There is.” Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ from those in the forward-looking statements. The content may differ significantly. Factors that could cause actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, the continued availability of capital and financing and general economic, market, or business situations. Investors are cautioned that such statements are not guarantees of future performance and actual results or developments may differ materially from those anticipated in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates, opinions or other factors change. not.
Neither the CSE nor its market regulator accepts responsibility for the adequacy or accuracy of this release as that term is defined in the policies of the CSE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/194966.
